The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
Abstract
Imatinib mesylate, a small-molecule inhibitor of BCRABL tyrosine kinase activity, has emerged as the well-recognized standard of treatment for chronic myelogenous leukemia (CML). Indeed, both its efficacy, tolerability, as well as cost-effectiveness have been clearly...
Paper Details
Title
The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
Published Date
Jul 1, 2008
Journal
Volume
2
Issue
2
Pages
67 - 68
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History